A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)
A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
RIO Negro
-
Viedma, RIO Negro, Argentina, 8500
- Local Institution
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H1M 1B1
- Local Institution
-
-
-
-
-
Dresden, Germany, 01307
- Local Institution
-
Gauting, Germany, 82131
- Local Institution
-
Gerlingen, Germany, 70839
- Local Institution
-
Grosshansdorf, Germany, 22927
- Local Institution
-
-
-
-
-
Lima, Peru
- Local Institution
-
Lima, Peru, 27
- Local Institution
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Local Institution
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Local Institution
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Local Institution
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Local Institution
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17604
- Local Institution
-
Langhorne, Pennsylvania, United States, 19047
- Local Institution
-
Sayre, Pennsylvania, United States, 18840
- Local Institution
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Local Institution
-
-
Utah
-
Saint George, Utah, United States, 84770
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- 1) Stage IV or recurrent non-Small cell lung cancer
- 2) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- 3) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization
Exclusion Criteria:
- 1) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
- 2) Active, known or suspected autoimmune disease or HIV infection
- 3) Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
- 4) Untreated Central Nervous System metastases
Other protocol defined inclusion/exclusion criteria could apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Flat-Dose
Nivolumab flat dose + Ipilimumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
EXPERIMENTAL: Weight-Based Dose
Nivolumab weight-based dose + Ipilimumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events
Time Frame: Approximately 3 months
|
Approximately 3 months
|
|
Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events
Time Frame: Approximately 3 months
|
Approximately 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
|
Overall survival (OS) as defined as the time from first dosing to the date of death
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame: Up to 24 months
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
- Ipilimumab
Other Study ID Numbers
Other Study ID Numbers
- CA209-955
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.